BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Revenue

BridgeBio Pharma had revenue of $243.68M in the quarter ending June 30, 2026, with 120.39% growth. This brings the company's total for the last twelve months to $713.07M, up 202.39% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth. That makes BridgeBio Pharma the 9,274th largest company in the world by revenue and 2,039th in the United States.

• Revenue (ttm): $713.07M
• Revenue Growth: +202.39%
• P/S Ratio: 19.02
• Revenue / Employee: $710,936
• Employees: 1,003
• Market Cap: 13.56B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Net Product 362.37M 72.2%
• License and Services 128.32M 25.6%
• Royalty 11.39M 2.3%

By Geography

• United States 362.50M 72.2%
• Europe, Middle East, and Africa (EMEA) 127.03M 25.3%
• Asia-Pacific (APAC) 12.55M 2.5%

Fiscal year ended Dec 31, 2025 See the full BridgeBio Pharma breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	502.08M	280.17M	126.26%
Dec 31, 2024	221.90M	212.60M	2,285.27%
Dec 31, 2023	9.30M	-68.35M	-88.02%
Dec 31, 2022	77.65M	7.93M	11.38%
Dec 31, 2021	69.72M	61.47M	745.14%
Dec 31, 2020	8.25M	-32.31M	-79.66%
Dec 31, 2019	40.56M	-	-
Dec 31, 2018	-	-	-
Dec 31, 2017	-	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Aug 10, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue geography data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error